Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 14/20 | 0.50 |
| ▸ | PKLR | P30613 | 7/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4988082 | 0.86 | KMT2A (0.55) | PKMPKLRKMT2AL3MBTL1TDP1 | |
| SCHEMBL4992341 | 0.85 | MET (0.41) | KMT2A | |
| SCHEMBL4983025 | 0.82 | MEN1 (0.53) | PKMKMT2AMKNK1 | |
| SCHEMBL4989386 | 0.81 | MKNK1 (0.52) | PKMPKLRKMT2AL3MBTL1MKNK1 | |
| SCHEMBL4989331 | 0.81 | MKNK1 (0.43) | PKMKMT2AL3MBTL1MKNK1 | |
| SCHEMBL4986276 | 0.81 | POLB (0.47) | PKMKMT2AL3MBTL1MKNK1 | |
| SCHEMBL4988452 | 0.81 | MEN1 (0.51) | PKMKMT2AL3MBTL1 | |
| SCHEMBL4989313 | 0.80 | MKNK1 (0.51) | KMT2AL3MBTL1MKNK1 | |
| SCHEMBL4992568 | 0.79 | MEN1 (0.46) | PKMKMT2AL3MBTL1MKNK1 | |
| SCHEMBL4993378 | 0.78 | KMT2A (0.49) | PKMKMT2AL3MBTL1MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | PKM 1098/4885PKLR 1213/4885KMT2A 4614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.